{"organizations": [], "uuid": "806aa730aea58bd6e4c5f956e92e65595f69b986", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aptevo-therapeutics-begins-patient/brief-aptevo-therapeutics-begins-patient-dosing-in-phase-2-clinical-trial-of-otlertuzumab-in-peripheral-t-cell-lymphoma-idUSASB0C04R", "country": "US", "domain_rank": 408, "title": "BRIEF-Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Trial Of Otlertuzumab In Peripheral T-Cell Lymphoma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.985, "site_type": "news", "published": "2018-01-08T22:10:00.000+02:00", "replies_count": 0, "uuid": "806aa730aea58bd6e4c5f956e92e65595f69b986"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aptevo-therapeutics-begins-patient/brief-aptevo-therapeutics-begins-patient-dosing-in-phase-2-clinical-trial-of-otlertuzumab-in-peripheral-t-cell-lymphoma-idUSASB0C04R", "ord_in_thread": 0, "title": "BRIEF-Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Trial Of Otlertuzumab In Peripheral T-Cell Lymphoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aptevo therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Aptevo Therapeutics Inc:\n* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T22:10:00.000+02:00", "crawled": "2018-01-09T17:03:31.064+02:00", "highlightTitle": ""}